Novel GHRH agonist peptides (JI-38, MR-356, MR-409) reduced infarct size, decreased inflammatory cytokines, and promoted cardiac repair by increasing stem cell activity and blood vessel formation after heart attack in rats.
Reduced IL-2, IL-6, IL-10, TNF-αMR-409 significantly suppressed four major inflammatory cytokines one week after heart attack, addressing the harmful inflammation that drives heart failure progression
What the researchers found
Three GHRH agonists — JI-38, MR-356, and MR-409 — reduced myocardial infarct size in rats after four weeks of treatment compared to placebo. The treated hearts showed increased numbers of cardiac c-kit+ progenitor cells (cardiac stem cells), more cellular mitotic divisions (active cell regeneration), and higher vascular density (new blood vessel formation).
One week after heart attack, MR-409 significantly reduced plasma levels of four inflammatory cytokines: IL-2, IL-6, IL-10, and TNF-α compared to placebo. Gene expression analysis revealed that MR-409 treatment inhibited pro-apoptotic molecules (cell death signals) and pro-fibrotic pathways (scarring) while elevating bone morphogenetic proteins involved in tissue repair. In cell culture, GHRH agonists decreased harmful calcium influx and improved cell survival under nutrient deprivation conditions.
Why it matters
Heart failure after heart attack is a leading cause of death worldwide, and current treatments only slow progression rather than repair damage. GHRH agonists represent a new peptide-based approach that addresses multiple aspects of cardiac repair simultaneously: reducing inflammation, preventing scar formation, activating cardiac stem cells, and promoting new blood vessel growth. This multi-mechanism action could make them more effective than single-target therapies.
How the study worked
In vitro, H9c2 cardiac cells were cultured in serum-free medium to mimic nutrient deprivation after heart attack. GHRH agonists were tested for effects on calcium influx and cell survival. In vivo, rats with surgically induced myocardial infarction were treated with GHRH agonist peptides or placebo for four weeks. Outcomes included infarct size measurement, counting of c-kit+ cardiac progenitor cells and mitotic divisions, vascular density assessment, plasma cytokine levels (ELISA), and gene expression profiling for apoptotic, fibrotic, and repair pathways.
What this study cannot tell us
This is a preclinical study in rats with surgically induced heart attacks — a model that doesn't fully replicate human coronary disease. The four-week treatment period is relatively short, and long-term effects on cardiac remodeling are unknown. Growth hormone-related peptides could potentially stimulate undesirable cell growth in other tissues, which needs safety evaluation. The study used multiple agonists with varying potencies but didn't establish optimal dosing for clinical translation. Gene expression changes don't guarantee functional cardiac improvement.
How to read the evidence
This is a preclinical study combining in vitro cardiac cell experiments with in vivo rat infarction models. The evidence is strong for the animal model, with multiple complementary endpoints (histology, cytokines, gene expression, cell survival). However, translation to human cardiac repair requires safety evaluation and clinical trials.
When this study was published
Published in 2015, this study is about a decade old. GHRH agonists for cardiac repair have continued to be explored in preclinical research since then, though clinical trials for this indication remain limited.
The bigger picture
GHRH is traditionally known for stimulating growth hormone release from the pituitary gland, but this study reveals direct cardiac effects through GHRH receptors expressed on heart cells. This 'extrapituitary' action of GHRH peptides is part of a growing recognition that hormonal peptides have broader tissue-specific functions beyond their classical endocrine roles. If translated to humans, GHRH agonists could complement existing heart failure treatments by actively promoting regeneration rather than just managing symptoms.
Questions still open
- Would GHRH agonist treatment be safe long-term given potential concerns about growth hormone-related effects on other tissues?
- Could these peptides be administered immediately after heart attack in an acute care setting to minimize damage?
- How do the cardiac repair effects of GHRH agonists compare to stem cell therapy and other regenerative medicine approaches?
Common questions
What is GHRH and why would it help a damaged heart?
Could these peptides actually regenerate damaged heart tissue?
Read the original research
New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor.
Oncotarget, 6(12), 9728-39
Citation
Kanashiro-Takeuchi, Rosemeire M; Szalontay, Luca; Schally, Andrew V; Takeuchi, Lauro M; Popovics, Petra; Jaszberenyi, Miklos; Vidaurre, Irving; Zarandi, Marta; Cai, Ren-Zhi; Block, Norman L; Hare, Joshua M; Rick, Ferenc G. (2015). New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor.. Oncotarget, 6(12), 9728-39.